Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 19/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.60 |
| ▸ | HTR2C | P28335 | 11/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1167093 | 0.89 | HTR2A (0.76) | HTR2AKCNH2HTR2C | |
| SCHEMBL18940866 | 0.84 | HTR2A (0.62) | HTR2AKCNH2HTR2C | |
| SCHEMBL884094 | 0.81 | HTR2A (0.79) | HTR2AKCNH2HTR2C | |
| SCHEMBL884361 | 0.80 | HTR2A (0.79) | HTR2AKCNH2HTR2C | |
| SCHEMBL21303286 | 0.80 | HTR2A (0.85) | HTR2AKCNH2HTR2C | |
| SCHEMBL1165520 | 0.78 | HTR2A (0.84) | HTR2AKCNH2HTR2C | |
| SCHEMBL1166625 | 0.78 | HTR2A (0.88) | HTR2AKCNH2HTR2C | |
| SCHEMBL883962 | 0.78 | HTR2A (0.80) | HTR2AKCNH2HTR2C | |
| SCHEMBL1166863 | 0.77 | HTR2A (0.86) | HTR2AKCNH2HTR2C | |
| SCHEMBL1166821 | 0.77 | HTR2A (0.82) | HTR2AKCNH2HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE45337-E1 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8148418-B2 | Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186895-A1 | ETHERS, SECONDARY AMINES AND DERIVATIVES THEREOF AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | HTR2A, HTR5A, HTR2C | HTR2A 1/4885KCNH2 1018/4885HTR2C 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.